Nivolumab Added to Cisplatin and Radiotherapy Improves DFS in Patients with High-Risk Resected Locally Advanced SCCHN By Ogkologos - January 9, 2026 88 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the GORTEC 2018-01 NIVOPOST-OP study Source RELATED ARTICLESMORE FROM AUTHOR Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up PAXG Significantly Improves EFS Compared with mFOLFIRINOX in Patients with Resectable or Borderline Resectable Pancreatic Ductal Adenocarcinoma EMA Recommends Extension of Therapeutic Indications for Retifanlimab MOST POPULAR Mom Is Warning Other Parents After Her Son Was Bit By... May 24, 2019 FDA Grants Accelerated Approval to Datopotamab Deruxtecan-dlnk for EGFR-mutated Non-Small Cell... July 11, 2025 EMA Recommends Granting a Marketing Authorisation for Equidacent August 6, 2020 Efficacy and Safety of Futibatinib in Patients with Previously Treated Intrahepatic... January 24, 2023 Load more HOT NEWS DNA from Ancient Viruses Helps Many Cancers Grow For Some Kids with Brain Cancer, Targeted Therapy is Better than... BREAKING: President Trump May Restore The WHO’s Funding, With Some Conditions 2021 ASCO Annual Meeting Research Round Up: New Research in Gynecologic...
